Table 1. Detection of CD11c and CD11c −... | American Society of Hematology

Table 1.

Detection of CD11c⁺ and CD11c⁻ DC subsets in FL-treated individuals

Individual	Day	Percent of PBMCs		Number of cells (×10⁻⁶/mL)
Individual	Day	CD11c⁺	CD11c⁻	CD11c⁺	CD11c⁻
FL	1	1.06 ± 0.2	0.83 ± 0.2	0.020 ± 0.007	0.016 ± 0.003
	15	14.74 ± 3.7	3.10 ± 0.6	0.879 ± 0.325	0.185 ± 0.018
Placebo	1	1.04 ± 0.2	0.75 ± 0.2	0.017 ± 0.007	0.012 ± 0.003
	15	1.02 ± 0.3	0.82 ± 0.2	0.018 ± 0.009	0.014 ± 0.004

Individual	Day	Percent of PBMCs		Number of cells (×10⁻⁶/mL)
Individual	Day	CD11c⁺	CD11c⁻	CD11c⁺	CD11c⁻
FL	1	1.06 ± 0.2	0.83 ± 0.2	0.020 ± 0.007	0.016 ± 0.003
	15	14.74 ± 3.7	3.10 ± 0.6	0.879 ± 0.325	0.185 ± 0.018
Placebo	1	1.04 ± 0.2	0.75 ± 0.2	0.017 ± 0.007	0.012 ± 0.003
	15	1.02 ± 0.3	0.82 ± 0.2	0.018 ± 0.009	0.014 ± 0.004

PBMCs were isolated from the blood of FL-treated and placebo-treated individuals at days 1 and 15 and analyzed by flow cytometry for the proportion and total number of CD11c⁺IL-3R-α⁻ and CD11c⁻IL-3R-α⁺ DCs per milliliter of blood. The data represent the mean ± SEM of 15 FL-treated and 5 placebo-treated individuals from all groups tested.

View Large

This Feature Is Available To Subscribers Only